CollPlant Biotechnologies Ltd New
Research CollPlant Biotechnologies Ltd New (CLGN) on Bullrun: market cap USD 4.18M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCLGN
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 4.18M
- Financial periodQ1 2026
- RevenueUSD 73.00K
- Net income-USD 3.10M
- Free cash flow-USD 3.06M
- Gross margin-332.9%
Valuation Snapshot
latest market cap is USD 4.18M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.37M | -USD 11.49M | -USD 9.45M | 64.8% | -0.94 | USD 5.59M | USD 2.85M | USD 6.08M |
| FY2024 | USD 515.00K | -USD 16.61M | -USD 14.58M | -215.5% | -1.45 | USD 11.91M | USD 3.08M | USD 13.47M |
| FY2023 | USD 10.96M | -USD 7.02M | -USD 3.72M | 81.8% | -0.62 | USD 26.67M | USD 3.16M | USD 28.34M |
| FY2022 | USD 299.00K | -USD 16.93M | -USD 14.97M | -33.8% | -1.53 | USD 29.65M | USD 321.00K | USD 32.28M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 4.18M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 17.92M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 41.24M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 73.18M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 93.41M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 176.23M | n/a | n/a | n/a |
About CollPlant Biotechnologies Ltd New
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CollPlant Biotechnologies Ltd New's market cap?
CollPlant Biotechnologies Ltd New's market capitalization is USD 4.18M.
What does CollPlant Biotechnologies Ltd New do?
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology.